J Med Life Sci > Volume 13(2); 2016 > Article
Journal of Medicine and Life Science 2016;13(2):111-116.
DOI: https://doi.org/10.22730/jmls.2016.13.2.111    Published online December 18, 2018.
과민성방광 환자에서 botulinum toxin A (Botoxⓡ) 치료에 대한 임상적 접근
, , , ,
Clinical approach of botulinum toxin A (Botoxⓡ) of treatment for patients with overactive bladder
Kyung Hoe Kim, Jung-Sik Huh, Young Joo Kim, Kyung kgi Park, Sung Dae Kim
Correspondence:  Sung Dae Kim,
Candidates for botulinum toxin A are generally patients with overactive bladder(OAB) whose disease is in adequately controlled with behavioral therapy and oral medication. All patients must be willing and able to perform clean intermittent catheterization(CIC). Before the decision to administer botulinum toxin A is made, the clinician should provide counseling to the patient regarding the agent’s indications, proposed benefis, risks, and mode of administration. The patient should be aware that botulinum toxin A takes effect after approximately 1?2weeks and usually lasts for 4?10months, after which repeat injections will be necessary to maintain effect. Patient preparation may include pre-treatment antibiotics and withdrawal of antiplatelet therapy or anticoagulants. Preparation of the product involves reconstitution in sterile saline and dilution according to the planned dose. The injections are performed using a flxible or rigid cystoscope, and the procedure takes approximately 15 min. The initial follow-up visit occurs within 7?14 days, when evidence of adverse effects, including urinary retention, can be evaluated. Repeat injections can be scheduled as needed, but not sooner than 3 months. Currently, the total dose of botulinum toxin A should not exceed 360 U in a 3-month period for all indications, including those outside the urinary tract (i.e.,cosmetic, ophthalmologic,etc.). Overall, botulinum toxin A is effective, generally well tolerated, safe, and is relatively simple to provide.
Key Words: Bladder, Overactive, Botulinum toxin, Treatment
METRICS Graph View
  • 0 Crossref
  •  0 Scopus
  • 869 View
  • 6 Download
Related articles

Editorial Office
102, Jejudaehak-ro, Jeju-si, Jeju-do 63243, Republic of Korea
Tel: +82-64-754-8023    E-mail: jmls.jeju@gmail.com                

Copyright © 2024 by Jeju National University Institute for Medical Science.

Developed in M2PI

Close layer
prev next